Stock Market Reviews

RADX (Radiopharm Theranostics Limited) News

Get the latest news, insights, and market updates on RADX (Radiopharm Theranostics Limited). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Radiopharm (RADX) Sees Slight Pessimism From Analysts
  We recently published 7 Best ASX Stocks to Buy Right Now. Radiopharm Theranostics Limited (NASDAQ:RADX) is one of the best ASX stocks. Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company developing treatments for ailments such as brain metastasis and prostate cancer. B. Riley lowered its share price target for the firm to $13 from $15 and […]
  Dec 15, 2025 - $RADX
• Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
  RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons SYDNEY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has been granted Bellberry Human Researc
  Nov 18, 2025 - $RADX
• Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases
  Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to MRI Phase 2b clinical trial expected to complete enrollment and have topline data in 1H26 SYDNEY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the Phase 2
  Nov 17, 2025 - $RADX
• Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
  Data Safety Monitoring Committee approves advancing to a higher dose of 90mCi The first two Cohorts’ patients show tumor uptake and a favourable safety profile SYDNEY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the completion of enrollment for the second cohort of pat
  Nov 12, 2025 - $RADX
• Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
  Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference (“dbVIC”) held November 4th are now available for online viewing. VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloa
  Nov 5, 2025 - $RADX
• RADX: Program and Financial Updates
  By John Vandermosten, CFA NASDAQ:RADX READ THE FULL RADX RESEARCH REPORT On October 28 th , Radiopharm Theranostics Limited (NASDAQ:RADX) announced its first quarter cash flows in its Activities and Cash Flow Report, disclosing a cash balance of A$19.0 million as of September 30 th , 2025. During the quarter, the company received an R&D tax refund of A$4.6 million, producing a net cash burn
  Nov 3, 2025 - $RADX
• International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
  NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S. Representatives from participating companies based in Australia, China, Hong Kong, Germany, Spain, Sweden, and the Cayman Islands will respond to questions during formal presentations. The con
  Oct 31, 2025 - $RADX
• CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
  NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- In a release issued yesterday October 30, 2025 by Virtual Investor Conferences, please note several agenda items were modified. The corrected release follows: Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S. Representatives from participatin
  Oct 31, 2025 - $RADX
• Radiopharm Theranostics Expects to Raise $22.7 Million Via Private Placement, Shares Down Pre-Bell
  Radiopharm Theranostics (RADX) shares were down over 15% in recent Monday premarket activity after t
  Oct 20, 2025 - $RADX
• Radiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trial
  Radiopharm (RADX) Theranostics announced that it has received a positive recommendation from the Data Safety and Monitoring Committee to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the next dose level of 75mCi in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal Growth Factor Receptor 2-positive advanced solid tumors. The DSMC is a multidisciplinary committee that conducts detailed reviews of study data, discusses potential safety events and provides reco
  Oct 2, 2025 - $RADX